Introduction
Hyperthyroidism has been found to be associated not only with sinus tachycardia, one of its features, but also with several dysrhythmias and conduction disturbances such as atrial flutter (Ernstene, 1938) , first and second degree of a.v. block (Cookson, 1959; Blizzard and Rupp, 1960; Hoffman and Lowrey, 1960; Rosenblum and Delman, 1963 ; Lanfranchi and Fauchier, 1973) , third degree of a.v. block (Davis and Smith, 1933; Steuer, 1936; Muggia, Stjernholme and Houle, 1970; Stern, Jacobs and Duncan, 1970; Kernoff, Rossouw and Kennelly, 1972) , reversible bundle branch block (Digilio, 1938) , ventricular ectopic beats (Rohrbach, 1968) , ventricular tachycardia (Ernstene, 1938; Fairhurst and Sash, 1959; Lyngborg and Jacobsen, 1972) and ventricular fibrillation (Boone, 1945; Lyngborg and Jacobsen, 1972) . These dysrhythmias, although some are rare, have been described in patients of over 40 years of age who also had coronary artery disease, hypertension or acute infections. Ernstene (1938) found 207 patients with atrial fibrillation among 1000 patients with hyperthyroidism, Bourel et al. (1969) twenty-four of eighty-three patients, Rohrbach (1968) four of eleven patients with masked hyperthyroidism, Sandler and Wilson (1959) (Friedberg, 1966; Miyahara et al., 1969) . It is common experience that no parallelism exists between heart rhythm and the severity of thyroid dysfunction (Friedberg, 1966) . Sinus rhythm is not always restored by normalizing the thyroid function and DC shock, quinidine or combination of drug therapy is often required to restore sinus rhythm.
Lidoflazine, a new anti-anginal drug, has been she,wn to have anti-arrhythmic activity, especially as concerns supraventricular dysrhythmias such as atrial fibrillation and flutter, in patients with arteriosclerosis, rheumatic heart disease, hypertension, congenital heart disease and lone atrial fibrillation (Miyahara et al., 1969; Piessens, Kesteloot and De Geest, 1970; Schlepper and Derro, 1972; Batlouni, unpublished report; De Vil and Bruyneel, 1974 Patients with manifest heart failure, special diets (low salt, low calorie) or acute coronary artery disease were excluded unless conditions were altered.
No other anti-arrhythmic drug was given except digitalis when required in the presence of heart failure or fast ventricular rhythm at rest (> 100 beats/min).
Lidoflazine tablets of 60 mg were given, starting with one tablet a day during the first week with a weekly increase of one tablet up to three tablets a day for the outpatients. The treatment was started with two or three tablets a day at once for the inpatients. Anti-hyperthyroid treatment was started before or after the cardioversion. The cardioversion was initially attempted in the hospital but later as an outpatient treatment. Hyperthyroidism was believed to be present according to the clinical features and symptoms and when plasma cholesterol was below 150 mg%, PBI above 9y, basal metabolism above + 30%, T3 resine uptake above 35%, T4 above 12 mg%.
Atrial fibrillation and sinus rhythm were diagnosed by means of repetitive 12-lead ECG recordings at rest. Lidoflazine treatment was maintained at the dose of cardioversion or less for each patient.
Results
Sinus rhythm was obtained in all six patients within half a day to 6 weeks (see Table 1 ). None of the patients had a history of arterial embolism or signs of mitral valve disease. Anticoagulants were given to one patient only (case 2). (De Vil and Bruyneel, 1974) and quinidine with propranolol (Levi and Proto, 1972) . Therefore it is difficult to agree with other authors (Carlier, 1973) who consider attempts to convert atrial fibrillation during hyperthyroidism to be utopian since sinus rhythm will not remain so long as hyperthyroidism exists, and most patients convert spontaneously to sinus rhythm once hyperthyroidism is effectively treated (Schrire, 1971; Carlier, 1973) . Ernstene (1938) (Erstene, 1938; Boone, 1945; Jervell, 1952; Moe, 1968 (Ernstene, 1938) and atrial fibrillation was found to be related with the duration of existence of hyperthyroidism (Willius, Boothby and Wilson, 1923) .
Other authors (Kulbertus, 1973) could not confirm this concept. However, some evidence that atrial fibrillation is not caused by hyperthyroidism itself but, more likely, is induced by the excess of thyroid hormones and maintained only in the presence of different kinds and degrees of cardiovascular damage, is given by the following facts.
(1) Chronic atrial fibrillation associated with hyperthyroidism occurs only in patients of over 40 years of age while atrial fibrillation in the younger patients remains paroxysmal (Boone, 1945) .
(2) Only 20-25% of all hyperthyroid patients develop chronic atrial fibrillation (Ernstene, 1938; Jervell, 1952; Sandler and Wilson, 1959; Rohrbach, 1968; Bourel et al., 1969) .
(3) Onset and spontaneous conversion of atrial fibrillation does not correspond to onset and correction of hyperthyroidism (Willius et al., 1923; Symons, Richardson and Wood, 1971) .
(4) Not all efficiently treated hyperthyroid patients with atrial fibrillation subsequently spontaneously regain sinus rhythm (Ernstene, 1938; Silver et al., 1962; Bock and Klein, 1972 (Cookson, 1959; Fairhurst and Sash, 1959; Lyngborg and Jacobsen, 1972) . Therefore, there is no need to leave the hyperthyroid patient, with his disturbing symptoms of palpitations or atrial fibrillation with fast ventricular rate and decreased cardiac output and effort tolerance (Benchimol, Lowe and Akre, 1965; Bouma and May, 1967) , until stable euthyroid state is obtained and hoping atrial fibrillation will spontaneously convert to sinus rhythm. Although propranolol (Howitt and Rowlands, 1966) , guanethidine (Lee, Bronsky and Waldstein, 1962; Waldstein et al., 1964; Goldstein and Killip, 1965) and reserpine (Canary et al., 1957) have been shown to diminish palpitations in patients with hyperthyroidism, they do not convert atrial fibrillation to sinus rhythm, and a complete return to normal conditions of heart rate and cardiac output is not achieved. Propranolol (Howitt and Rowlands, 1967) and guanethidine (Goldstein and Killip, 1965) should be used with caution in hyperthyroidism since both drugs reduce blood flow to certain vascular beds out of proportion to the oxygen demand. Another alternative is offered by lidoflazine therapy. This original compound prolongs reactive hyperaemia in mini pigs after coronary artery occlusion (Jageneau, Schaper and Van Gerven, 1969) , reduces consumption of nitroglycerine tablets and improves exercise tolerance in patients with coronary heart disease (Batlouni, Bertolami and Duprat, 1968; Bernstein and Peretz, 1972; Piessens and De Geest, 1972) . Lidoflazine converts atrial fibrillation to sinus rhythm in 70-80% of the patients suitable for cardioversion and the therapy compares favourably with quinidine-induced conversions (De Vil and Bruyneel, 1974) .
The rate of pacemaker activity and depolarization (dV/dt) and amplitude of the action potential and conduction velocity of in vitro cardiac muscle preparations are reduced by lidoflazine. The duration of the action potential and of the effective refractory period is prolonged (Carmeliet and Xhonneux, 1971) . Lidoflazine may thus be compared to local anaesthetics and other anti-arrhythmic drugs, such as quinidine. It has no obvious chronotropic (Keulen, 1973) or inotropic (Bruyneel, personal observation) effect in the resting state. Lidoflazine is not known to interfere with the thyroid hormone metabolism or any of its diagnostic tests. Bernstein and Peretz (1972) found QTc to be prolonged in their patients with lidoflazine. Keulen (1973) found the QTc unchanged. Increased incidence of ventricular dysrhythmias has been reported during lidoflazine treatment in patients with atrial fibrillation and overt heart failure, enlarged heart size or conditions where decreased body potassium can be expected (Piessens et al., 1970; Schlepper and Derro, 1972) . This was not the experience when classic selection criteria for cardioversion were applied (De Vil and Bruyneel, 1974) .
The advantages of lidoflazine therapy seem to be the absence of side effects and drug interference and the low dosage needed to maintain sinus rhythm with excellent results after cardioversion. Batlouni (unpublished report) found twenty-eight of thirty patients with atrial fibrillation to be still in sinus rhythm 1 year after having been converted to sinus rhythm with lidoflazine. Twenty-four patients had taken one tablet daily for 1 year as maintenance therapy. Our limited experience with lidoflazine in hyperthyroid patients with atrial fibrillation accords with previous observations as concerns its efficacy to convert atrial fibrillation to sinus rhythm and its maintenance. It confirms the intrinsic antiarrhythmic effect of lidoflazine which is obvious within a few days or weeks in contrast to its antianginal effect which starts after 2-3 months of therapy.
